Oasmia Pharmaceutical AB
OASM
OASM was delisted on the 21st of August, 2019.
6 hedge funds and large institutions have $2.89M invested in Oasmia Pharmaceutical AB in 2015 Q4 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.61M |
| 2 |
SCM
Sio Capital Management
New York
|
+$484K |
| 3 |
Jane Street
New York
|
+$41.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$7.47K |
| 5 |
Morgan Stanley
New York
|
+$16 |
Top Sellers
OASM Hedge Fund Activity: Q4 2015 in Review
6 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Oasmia Pharmaceutical AB (OASM) for Q4 2015, worth a combined $2.89M.
Buyers outnumbered sellers: 6 funds opened new OASM positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $2.61M.
- 6 institutional investors held Oasmia Pharmaceutical AB (OASM) as of Q4 2015, up from 0 in Q3 2015.
- Funds reported $2.89M of Oasmia Pharmaceutical AB stock for Q4 2015.
- 6 funds opened new Oasmia Pharmaceutical AB positions in Q4 2015 and 0 closed out, a net change of +6 holders.
- The largest Oasmia Pharmaceutical AB buyer in Q4 2015 was Sabby Management, an estimated $2.61M added.
Based on aggregated 13F filings for Q4 2015.